FERRING-PHARMACEUTICALS
Ferring Pharmaceuticals and Enteris BioPharma, Inc. announced today that the companies have entered into a license agreement and initiated an early development agreement to leverage Enteris’ proprietary and patented oral peptide and small molecule delivery platform, Peptelligence™, to engineer an oral formulation of a peptide-based injectable therapeutic developed by Ferring.
Under the terms of the agreement, Enteris BioPharma will license to Ferring its oral drug delivery technologies, as well as provide clinical trial finished product, and will receive milestones and royalties based on net sales of the developed product.
The licensing agreement with Ferring Pharmaceuticals highlights Enteris BioPharma’s successful “Feasibility-to-Licensing” strategy involving Peptelligence™, its peptide and small molecule oral drug delivery platform. The technology is currently the subject of several active external development programs and has proven effective over the last decade to enable the safe delivery of peptide-based therapeutics and other molecules with low oral bioavailability.
Joel Tune, Chief Executive Officer and Executive Chairman of Enteris BioPharma, remarked, “Our agreement with Ferring Pharmaceuticals exemplifies the opportunity our Peptelligence platform offers in enhancing the market potential of peptide-based therapeutics by enabling the oral delivery of medications that must otherwise be administered by injection. We are excited to work with an industry leader like Ferring Pharmaceuticals to advance the development of an oral peptide-based therapeutic.”
Alan Harris, Senior Vice President, R&D Executive Office of Ferring Pharmaceuticals, remarked, “The ability to deliver oral peptides offers Ferring the opportunity to provide additional therapeutic choices to patients. We are impressed with Enteris’ proprietary oral delivery technology and look forward to working with them to advance this development program.”
ENDS
About Ferring Pharmaceuticals
Headquartered in Switzerland, Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group active in global markets. The company identifies, develops and markets innovative products in the areas of reproductive health, urology, gastroenterology, endocrinology and orthopaedics. Ferring has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries. To learn more about Ferring or its products please visit www.ferring.com .
About Enteris BioPharma
Enteris BioPharma, Inc. is a privately held, New Jersey-based biotechnology company offering innovative formulation solutions built around its proprietary drug delivery technologies. The Company’s proprietary oral delivery technology – Peptelligence™ - has been the subject of numerous feasibility studies and active development programs, several of which are in late stage clinical development. Additionally, Enteris BioPharma has built and is advancing an internal product pipeline of oral tablet reformulations of drug products that address significant treatment opportunities for which there is no oral delivery option. Enteris BioPharma’s most advanced internal product candidate, Ovarest™ (oral leuprolide tablet), is a Phase 2a-ready oral peptide, being developed for the treatment of endometriosis. For more information on Enteris BioPharma and its proprietary oral delivery technology and contract manufacturing capabilities, please visit www.enterisbiopharma.com .
View source version on businesswire.com: http://www.businesswire.com/news/home/20170130005558/en/
Contact:
Ferring Pharmaceuticals
Lindsey Rodger
Tel. +41 58 451
40 23
lindsey.rodger@ferring.com
or
Enteris
BioPharma:
Brian Zietsman, President & CFO
+1 973 453
3527
or
Enteris Media Relations:
Jason Rando / Amy
Wheeler
Tiberend Strategic Advisors, Inc.
+1 212 827 0020
jrando@tiberend.com
awheeler@tiberend.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bloom Announces Early 2026 UK Launch, Expanding into Europe with New Garden Pharma as Exclusive Manufacturer24.6.2025 07:05:00 CEST | Press release
The Bloom Brand, a recognized U.S. leader in cannabis vape, is making its international debut in the United Kingdom through an exclusive partnership with New Garden Pharma, a leading European EU-GMP cannabis operator. Together, the two companies will launch Bloom’s award-winning Classic and Live vape collections in the UK in Q1 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250623573625/en/ This marks Bloom’s first international market expansion, as the company continues its global growth strategy with additional EU markets in development for 2026 and beyond. UK patients will gain access to Bloom’s superior formulations and proprietary hardware systems. For more than a decade, Bloom has built its reputation on delivering terpene-rich, flavor-forward strains paired with reliable technology. The brand has an established and leading presence across leading U.S. markets including California, Illinois, Florida, Michigan, Mi
ACI Worldwide Expands Technology Partnership Ecosystem to Power ACI Connetic24.6.2025 07:00:00 CEST | Press release
ACI’s unified cloud-based payments platform to boost operational resiliency and support increasing non-functional requirements of modern payment systems ACI Worldwide (NASDAQ:ACIW), an original innovator in global payments technology, has expanded its global technology partnership ecosystem to help financial institutions across the globe increase operational resiliency and address evolving regulatory requirements to safeguard the stability of the financial system. Building on strategic partnerships with Microsoft, Red Hat and IBM, ACI is collaborating with MongoDB, a document-oriented NoSQL database, and open source technology NATS from Synadia Communications for the reference architecture of ACI Connetic, ACI’s unified, cloud-native payments platform. These partnerships help extend ACI Connetic far beyond a traditional payments hub, delivering robust, highly functional payment engines to support financial institutions in meeting growingly stringent non-functional requirements and incr
Industrial 3-axis accelerometer has high offset stability24.6.2025 04:00:00 CEST | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has introduced a 3-axis accelerometer for the industrial market that combines high offset stability over temperature and time, good linearity, low noise density, and excellent robustness. The SCA3400-D01 XYZ accelerometer is meant for use in industrial applications such as structural health monitoring (SHM), machine control, inertial measurement units, and construction tools and systems. This product will be exhibited at Sensors Converge 2025 to be held at the Santa Clara Convention Center (Booth #716), California from 24 to 26 June 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250623994075/en/ [Murata Manufacturing Co., Ltd.] Industrial 3-axis accelerometer The offset stability of an accelerometer refers to the consistency of its output when at rest, but subject to varying temperatures or the effects of aging. Ideally, this output should be zero, but i
Grid Dynamics Announces AI-Powered Engagement Model Enabling Accelerated Business Transformation for Fortune 1000 Enterprises23.6.2025 15:15:00 CEST | Press release
Key Takeaways: Grid Dynamics introduces an AI-powered engagement model for software delivery. This engagement model expands Grid Dynamics’ offerings by providing a fundamentally new way of delivering value—enabling clients to achieve superior outcomes by providing the next level of agility, quality, and accelerated time-to-market. The model is based on the Grid Dynamics AI-Native Development Framework (GAIN Development Framework)—a combination of proprietary processes, human capital, and an AI-Enabled Development Platform. This framework is designed specifically to support the scale and complexity of Fortune 1000 enterprises. Based on internal benchmarks, we expect this model to accelerate project delivery by achieving over 30% productivity improvements. Progressive credit-based pricing directly tied to performance and value is the basis of the new engagement model. Grid Dynamics Holdings, Inc. (Nasdaq: GDYN) (Grid Dynamics)—a prominent technology consulting and digital services provid
Live Biotherapeutics at a Crossroad: Novotech White Paper Outlines Opportunities and Early-Stage Challenges23.6.2025 14:05:00 CEST | Press release
As Live Biotherapeutic Products (LBPs) begin to transition from frontier science to clinical reality, Novotech, a leading global CRO and scientific advisory partner has published a new white paper examining the opportunities and challenges shaping this fast-evolving landscape of therapeutic class. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250623205345/en/ LBPs, which harness live microorganisms to restore or modulate human health, are being explored across a growing range of indications, from gastrointestinal and metabolic disorders to CNS and oncology. FDA approvals of Rebyota™ and Vowst™ have validated the category but for most biotech sponsors, the journey remains uncertain. According to Novotech’s analysis, over 90% of LBP assets are still in early development stages, and nearly one-third of all trials from 2020 to 2025 have been withdrawn or suspended due to regulatory, manufacturing, or design complexities. Highli
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom